Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Alector, Inc. is a clinical-stage biotechnology company focused on developing immuno-neurology therapies for neurodegenerative diseases. The company operates within the biotechnology and biopharmaceutical industries, with a core emphasis on leveraging the innate immune system to counteract disease progression in conditions such as frontotemporal dementia (FTD), Alzheimer’s disease, and other neurodegenerative disorders. Its approach centers on genetically validated targets associated with immune pathways in the central nervous system.
Alector was founded in 2013 and became a publicly traded company in 2019. Since inception, the company has evolved from early research into a pipeline-driven clinical organization advancing multiple monoclonal antibody programs. A key element of its development has been strategic collaboration with large pharmaceutical partners, most notably GlaxoSmithKline, which has supported both funding and clinical development efforts.
Business Operations
Alector operates as a single-reportable-segment biotechnology company, generating no product revenue to date and primarily funded through collaboration revenue, research funding, and public equity. Its business activities focus on discovery, development, and early-to-mid-stage clinical trials of antibody-based therapeutics targeting immune pathways such as progranulin and TREM2. Lead clinical programs include latozinemab (AL001) for FTD associated with progranulin deficiency and additional pipeline candidates targeting microglial biology.
The company conducts research and development primarily in the United States, with clinical trials executed across multiple international sites. Alector controls proprietary antibody discovery platforms and translational biology capabilities, while relying on third-party manufacturers and contract research organizations. A long-term strategic collaboration with GlaxoSmithKline provides co-development support, milestone payments, and shared global rights for select programs.
Strategic Position & Investments
Alector’s strategic direction is centered on advancing late-stage clinical assets while selectively expanding its pipeline through internal research and external partnerships. Growth initiatives emphasize genetically validated targets to reduce development risk and improve probability of clinical success. The collaboration with GlaxoSmithKline represents the company’s most significant strategic investment, involving multiple programs and shared commercialization rights.
The company has not completed major acquisitions but continues to invest heavily in immuno-neurology research and biomarker-driven clinical development. Emerging focus areas include microglial modulation, neuroinflammation, and immune-mediated neuroprotection. Some pipeline assets have been discontinued or reprioritized over time based on clinical data, reflecting an adaptive portfolio management approach.
Geographic Footprint
Alector is headquartered in South San Francisco, California, and its primary operations are based in the United States. Research, development, and corporate functions are centralized domestically, while clinical trials are conducted across North America, Europe, and select additional international regions depending on study design.
Through its partnership with GlaxoSmithKline, Alector has indirect global reach, including access to European and other international markets for collaborative programs. While the company does not maintain large overseas offices, its operational and clinical footprint spans multiple continents via trial sites and research collaborations.
Leadership & Governance
Alector was founded by Arnon Rosenthal, who continues to shape the company’s scientific and strategic direction. The leadership team combines biotechnology, neuroscience, and capital markets experience, with a governance philosophy centered on scientific rigor, genetic validation, and long-term value creation in neurodegenerative disease therapeutics.
Key executives include:
- Arnon Rosenthal – Co‑Founder and Chief Executive Officer
- Sara Kenkare – Chief Financial Officer
- Julie M. Chisholm – Chief Medical Officer
The executive team works closely with an experienced board of directors to oversee clinical strategy, capital allocation, and partnership management, with a stated focus on disciplined development and patient-centered innovation.